Fed. Circ. Tailors Arguments After Teva Skinny Label Outcry
A Federal Circuit panel zeroed in Tuesday on facts specific to whether Teva induced infringement of GlaxoSmithKline's drug Coreg in a do-over hearing after the panel's initial decision drew criticism that...To view the full article, register now.
Already a subscriber? Click here to view full article